The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: Olanzapine monotherapy

Psychoneuroendocrinology

Volumn 38, Issue 3, 2013, Pages 341-347

  Ak, Mehmet ^a   Sezlev, Deniz ^b   Sutcigil, Levent ^a   Akarsu, Suleyman ^a   Ozgen, Fuat ^a   Yanik, Tulin ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Melanocortine stimulating hormone; Leptin; Neuropeptide Y; Olanzapine; Weight gain

Indexed keywords

ALPHA INTERMEDIN; CHOLESTEROL; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; EDETIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LEPTIN; LOW DENSITY LIPOPROTEIN; NEUROPEPTIDE; NEUROPEPTIDE Y; OLANZAPINE; PROOPIOMELANOCORTIN; SEROTONIN; SEROTONIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARCUATE NUCLEUS; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHALAMUS; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PSYCHOSIS; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; ALPHA-MSH; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CHOLESTEROL; HUMANS; HYPOTHALAMUS; LEPTIN; MALE; NERVE TISSUE PROTEINS; NEUROPEPTIDE Y; NEUROPEPTIDES; PSYCHOTIC DISORDERS; WAIST CIRCUMFERENCE;

EID: 84875232827     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.06.012     Document Type: Article

References (44)

1. Air E.L., Strowski M.Z., Benoit S.C., Conarello S.L., Salituro G.M., Guan X.M., et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat. Med. 2002, 8(2):179-183.
2. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156:1686-1696.
3. Audinot V., Newman-Tancredi A., Cussac D., Millan M.J. Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors. Neuropsychopharmacology 2001, 25(3):410-422.
4. Banks W.A., Coon A.B., Robinson S.M., Moinuddin A., Shultz J.M., Nakaoke R., et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004, 53(5):1253-1260.
5. Beck B. Neuropeptides and obesity. Nutrition 2000, 16(10):916-923.
6. Benoit S.C., Air E.L., Coolen L.M., Strauss R., Jackman A., Clegg D.J., et al. The catabolic action of insulin in the brain is mediated by melanocortins. J. Neurosci. 2002, 22(20):9048-9052.
7. Bhana N., Foster R.H., Olney R., Plosker G.L. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001, 61:111-161.
8. Blundell J.E., Finlayson G. Is susceptibility to weight gain characterized by homeostatic or hedonic risk factors for overconsumption?. Physiol. Behav. 2004, 82:21-25.
9. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14(2):87-96.
10. Chen R.Z., Huang R.C., Shen C.P., MacNeil D.J., Fong T.M. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res. 2004, 999:227-230.
11. Chen V.C., Wang T.N., Lu M.L., Chou J.Y., Ju P.C., Wu J.Y., et al. Weight gain and ghrelin level after olanzapine monotherapy. Progr. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(2):632-635.
12. Clifton P.G., Lee M.D., Dourish C.T. Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berlin) 2000, 152(3):256-267.
13. De Hert M., Dobbelaere M., Sheridan E.M., Cohen D., Correll C.U. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur. Psychiatry 2011, (February). (E-pub ahead of print). 10.1016/j.eurpsy.2010.09.011.
14. de Leon J., Susce M.T., Johnson M., Hardin M., Pointer L., Ruaño G., et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 2007, 92(1-3):95-102.
15. De Vry J., Schreiber R. Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action. Neurosci. Biobehav. Rev. 2000, 24(3):341-353.
16. Eder U., Mangweth B., Ebenbichler C., Weiss E., Hofer A., Hummer M., et al. Association of olanzapine-induced weight gain with an increase in body fat. Am. J. Psychiatry 2001, 158(10):1719-1722.
17. Fernø J., Varela L., Skrede S., Vázquez M.J., Nogueiras R., Diéguez C., et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One 2011, 6(6):e20571. 10.1371/journal.pone.0020571.
18. Foster-Schubert K.E., Cummings D.E. Emerging therapeutic strategies for obesity. Endocr. Rev. 2006, 27(7):779-793.
19. Gail S.M., Castracane V.D., Mantzoros C.S. Energy homeostatis, obesity and eating disorders: recent advances in endocrinology. J. Nutr. 2004, 134(2):295-298.
20. Goldstein J.M. The new generation of antipsychotic drugs: how atypical are they?. Int. J. Neuropsychopharmacol. 2000, 3:339-349.
21. Hoggard N., Hunter L., Duncan J.S., Rayner D.V. Regulation of adipose tissue leptin secretion by alpha-melanocyte-stimulating hormone and agouti-related protein: further evidence of an interaction between leptin and the melanocortin signalling system. J. Mol. Endocrinol. 2004, 32:145-153.
22. Jequier E. Leptin signaling, adiposity and energy balance. Ann. N.Y. Acad. Sci. 2002, 967:379-388.
23. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr. Res. 2008, 100(1-3):70-85.
24. Karen E., Schubert F., Cummings D.E. Emerging therapeutic strategies for obesity. Endocrine Reviews 2006, 27(7):779-793.
25. Katsuki A., Sumida Y., Murashima S., Furuta M., Araki-Sasaki R., Tsuchihashi K., et al. Elevated plasma levels of alpha-melanocyte stimulating hormone (alpha-MSH) are correlated with insulin resistance in obese men. Int. J. Obes. Relat. Metab. Disord. 2000, 24(10):1260-1264.
26. Kirk S.L., Neill J.C., Jones D.N., Reynolds G.P. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur. J. Pharmacol. 2004, 505(1-3):253-254.
27. Konturek P.C., Konturek J.W., CzeŚnikiewicz-Guzik M., Brzozowski T., Sito E., Konturek S.J. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J. Physiol. Pharmacol. 2005, 56(6):5-25.
28. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
29. Parsons B., Allison D.B., Loebel A., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr. Res. 2009, 110:103-110.
30. Purdon S.E., Malla A., Labelle A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 2001, 26:137-149.
31. Ramos E.J., Meguid M.M., Campos A.C., Coelho J.C. Neuropeptide Y, alpha-melanocyte-stimulating hormone, and monoamines in food intake regulation. Nutrition 2005, 21(2):269-279.
32. Raposo N.R., Ferreira A.S., Gattaz W.F. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry 2011, 44(5):169-172.
33. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol. Ther. 2010, 125:169-179.
34. Schmidt A.W., Lebel L.A., Howard H.R., Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 2001, 425(3):197-201.
35. Schwartz M.W., Figlewicz D.P., Baskin D.G., Woods S.C., Porte D.J. Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. 1992, 13:387-414.
36. Schwartz M.W., Sipols A.J., Marks J.L., Sanacora G., White J.D., Scheurink A., et al. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 1992, 130:3608-3616.
37. Shutter J.R., Graham M., Kinsey A.C., Scully S., Luthy R., Stark K.L. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 1997, 11:593-602.
38. Sengul C., Herken H. Pharmacogenetics of antipsychotic-induced weight gain. Clin. Psychopahrmacol. Issue 2009, 19:298-304. (in Turkish).
39. Sengul C., Erdal M.E., Aydin N., Sengul C.B., Barlas O., Aynacioglu S., et al. The relation between IRS-1 Gly972Arg (insulin receptor substrate) gene polymorphism and olanzapine induced weight gain. J. Anatolian Psychiatry 2010, 11:18-22. (in Turkish).
40. Tandon R. Safety and tolerability: how do newer generation " atypical" antipsychotics compare?. Psychiatry 2002, 73:297-311.
41. Thornton J.E., Cheung C.C., Clifton D.K., Steiner R.A. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 1997, 138:5063-5066.
42. Tiligada W. Regulation of α-melanocyte stimulating hormone release from superfused slices from rat hypothalamus by seratonin and the interaction of setatonin with the dopaminergic system inhibiting peptide release. Brain Res. 1989, 503:225-228.
43. Wagner M., Quednow B.B., Westheide J., Schlaepfer T.E., Maier W., Kühn K.U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005, 30:381-390.
44. Yazici K., Yazici A. Antipsychotic-induced weight gain: the role of the genetics?. Clin. Psychopahrmacol. Issue 2008, 18:59-70. (in Turkish).